The GPS assay stratifies unfavorable intermediate-risk patients into two distinct groups with highly differing long-term outcomes
GPS ≤40 vs >40
GPS The GPS cut point of 40 stratifies Unfavorable Intermediate-Risk patients into two distinct subsets of patients with highly differing long-term outcomes.1
Unfavorable Intermediate-Risk Patients1,2
The Oncotype DX test reduces risks of over and undertreatment2
73% of patients with high clinical riska had Recurrence Score results 0–25 and may have been overtreated without the Recurrence Score result.2
High Clinical Risk Patients
Chemotherapy can potentially be spared
43% of patients with Recurrence Score results 26–100 had low clinical riska and may have been undertreated without the Recurrence Score result.2
Low Clinical Risk Patients
Chemotherapy can potentially be life-saving
a Low clinical risk defined by low grade and tumour size =3 cm, intermediate grade and tumour size =2 cm, and high grade and tumour size =1 cm; high clinical risk defined as all other cases with known values for grade and tumour size
Proven clinical utility of the Oncotype DX assay1-3,13,16
Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision using the Oncotype DX Breast Recurrence Score test to identify:
- the vast majority of patients who can safely be spared chemotherapy
- the important minority for whom chemotherapy may be life-saving